The PLCE1 (Phospholipase C Epsilon 1) antibody is a tool used to study the expression and function of the PLCE1 protein, a member of the phospholipase C (PLC) enzyme family. PLCE1 is encoded by the PLCE1 gene and plays a critical role in intracellular signaling by hydrolyzing phosphatidylinositol 4.5-bisphosphate (PIP2) into secondary messengers, inositol 1.4.5-trisphosphate (IP3) and diacylglycerol (DAG), which regulate calcium release and protein kinase C activation. Unlike other PLC isoforms, PLCE1 contains unique regulatory domains, including Ras-associating and CDC25 homology domains, enabling interaction with small GTPases like Ras and Rap1. This positions PLCE1 as a key mediator in pathways controlling cell proliferation, differentiation, and apoptosis.
PLCE1 antibodies are widely used in research to detect protein expression via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Studies link PLCE1 dysregulation to various diseases, including cancers (e.g., colorectal, gastric, and esophageal squamous cell carcinoma), inflammatory disorders, and nephrotic syndrome. For instance, PLCE1 mutations are implicated in hereditary nephrotic syndrome, while its overexpression in tumors correlates with aggressive progression.
These antibodies aid in exploring PLCE1's role in disease mechanisms, therapeutic targeting, and biomarker discovery. Their specificity and validation across experimental models make them essential for dissecting PLCE1's complex signaling networks in health and disease.